– Reuters
Morgan Stanley Maintains Equal-Weight on ICL Group, Raises Price Target to $9
Morgan Stanley analyst Vincent Andrews maintains ICL Group (NYSE:ICL) with a Equal-Weight and raises the price target from $7 to $9.
Related Posts
Aligos Co-Founders File Complaint Against Johnson & Johnson Alleging Fraud
Aligos Therapeutics Inc (NASDAQ:ALGS) has filed a response to the complaint of and counterclaims against Janssen Biopharma. In November 2014, Johnson…
Credit Suisse Maintains Outperform on Ascendis Pharma, Raises Price Target to $194
Credit Suisse analyst Tiago Fauth maintains Ascendis Pharma (NASDAQ:ASND) with a Outperform and raises the price target from $188 to $194.
